Parkside Financial Bank & Trust Bio Xcel Therapeutics, Inc. Transaction History
Parkside Financial Bank & Trust
- $742 Million
- Q4 2024
A detailed history of Parkside Financial Bank & Trust transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 1,800 shares of BTAI stock, worth $540. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,800
Previous 1,800
-0.0%
Holding current value
$540
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BTAI
# of Institutions
52Shares Held
3.11MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$360,4130.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$132,2050.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$89,4120.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$55,5170.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$38,9600.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $8.41M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...